Trial Profile
An Open-label Randomized Study to Evaluate the Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203) in Treatment-naïve Patients With Newly Diagnosed Drug-sensitive Sputum Smear-positive Pulmonary Tuberculosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2020
Price :
$35
*
At a glance
- Drugs Telacebec (Primary) ; Rifampicin/isoniazid/pyrazinamide/ethambutol
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Sponsors Qurient Co
- 25 Mar 2020 According to an Qurient Co media release, this trial is led by global key opinion leaders in TB located in Cape Town, South Africa: Professor Andreas Diacon, a national principal investigator at TASK Applied Science, Doctor Veronique de Jager, principal investigator at TASK Applied Science, and Professor Rodney Dawson, principal investigator at University of Cape Town Lung Institute.
- 25 Mar 2020 According to an Qurient Co media release, data from this trial were published in New England Journal of Medicine.
- 25 Mar 2020 Results presented in an Qurient Co media release.